ReviewWorld journal of gastroenterology2017
Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review.
Review in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Prevalence of Mpox vaccine acceptance and hesitancy among people living with HIV: a comprehensive systematic review and meta-analysis.AIDS research and therapy · 2025Pooled it
- A systematic review and meta-analysis of predictors of human hepatitis E virus exposure in non-endemic countries.Zoonoses and public health · 2020Pooled it
- Hepatitis A virus knowledge and immunization attitudes and practices in the United Arab Emirates community.Scientific reports · 2021Trial
- Immunogenicity persistence in children of hepatitis A vaccines Healive® and Havrix®: 11 years follow-up and long-term prediction.Human vaccines & immunotherapeutics · 2020Trial
- Hepatitis A to E in People with HIV: A Virus-Specific Review of Prevention and Treatment.Infectious diseases and therapy · 2026Review
- Acute hepatitis a complicated by rhabdomyolysis in a young adult: a diagnostic challenge.Oxford medical case reports · 2025Article
- Review
- Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses.Biological procedures online · 2025Review
- Regional and age related variations in hepatitis A virus incidence in China 2004 to 2018: a descriptive epidemiological study.Scientific reports · 2025Article
- Atomic force microscopy at the forefront: unveiling foodborne viruses with biophysical tools.Npj viruses · 2025Review
- Hepatitis A Seroprevalence Among HIV-Exposed and Unexposed Pediatric Populations in South Africa.Vaccines · 2024Article
- Concurrent Outbreaks of Hepatitis A, Invasive Meningococcal Disease, and Mpox, Florida, USA, 2021-2022.Emerging infectious diseases · 2024Review
- [Expert recommendations on hepatitis A vaccination for adults].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: a 5-year follow-up study.Emerging microbes & infections · 2023Article
- State-of-the-Science of human papillomavirus vaccination in women with human immunodeficiency Virus: Summary of a scientific workshop.Preventive medicine reports · 2023Review
- Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus.Viruses · 2023Review
- The Seroprevalence of Hepatitis A in Patients with Positive Human Immunodeficiency Virus.Middle East journal of digestive diseases · 2023Article
- Living with HIV and Getting Vaccinated: A Narrative Review.Vaccines · 2023Review
- Norovirus, Hepatitis A and SARS-CoV-2 surveillance within Chilean rural wastewater treatment plants based on different biological treatment typologies.The Science of the total environment · 2023Article
- Sex differences in hepatitis A incidence rates-a multi-year pooled-analysis based on national data from nine high-income countries.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV) is one of the most common infectious etiologies of acute hepatitis worldwide. The virus is known to be transmitted fecal-orally, resulting in symptoms ranging from asymptomatic infection to fulminant hepatitis. HAV can also be transmitted through oral-anal sex. Residents from regions of low endemicity for HAV infection often remain susceptible in their adulthood. Therefore, clustered HAV infections or outbreaks of acute hepatitis A among men who have sex with men and injecting drug users have been reported in countries of low endemicity for HAV infection. The duration of HAV viremia and stool shedding of HAV may be longer in human immunodeficiency virus (HIV)-positive individuals compared to HIV-negative individuals with acute hepatitis A. Current guidelines recommend HAV vaccination for individuals with increased risks of exposure to HAV (such as from injecting drug use, oral-anal sex, travel to or residence in endemic areas, frequent clotting factor or blood transfusions) or with increased risks of fulminant disease (such as those with chronic hepatitis). The seroconversion rates following the recommended standard adult dosing schedule (2 doses of HAVRIX 1440 U or VAQTA 50 U administered 6-12 mo apart) are lower among HIV-positive individuals compared to HIV-negative individuals. While the response rates may be augmented by adding a booster dose at week 4 sandwiched between the first dose and the 6-mo dose, the need of booster vaccination remain less clear among HIV-positive individuals who have lost anti-HAV antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.